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E-mail: h.mccarthy@qub.ac.ukWound healing is a highly complex biological process
composed of three overlapping phases: inﬂammation, prolifer-
ation, and remodeling. Impairments at any one or more of
these stages can lead to compromised healing. MicroRNAs
(miRs) are non-coding RNAs that act as post-transcriptional
regulators of multiple proteins and associated pathways.
Thus, identiﬁcation of the appropriate miR involved in the
different phases of wound healing could reveal an effective
third-generation genetic therapy in chronic wound care.
Several miRs have been shown to be upregulated or downregu-
lated during the wound healing process. This article examines
the biological processes involved in wound healing, the miR
involved at each stage, and how expression levels are modulated
in the chronic wound environment. Key miRs are highlighted
as possible therapeutic targets, either through underexpression
or overexpression, and the healing beneﬁts are interrogated.
These are prime miR candidates that could be considered as a
gene therapy option for patients suffering from chronic
wounds. The success of miR as a gene therapy, however, is
reliant on the development of an appropriate delivery system
thatmust be designed to overcome both extracellular and intra-
cellular barriers.
Introduction to Wound Healing
The largest organ of the human body is the skin; it accounts for
approximately 15% of total body weight in adults.1,2 The skin acts
as a protective barrier against the environment and helps to prevent
dehydration. The skin has three distinct layers: (1) epidermis,
composed mainly of keratinocyte cells; (2) dermis, which is a
collagen-rich tissue containing blood and lymph vessels, ﬁbroblasts,
macrophages, and neutrophils; and (3) hypodermis, which is con-
structed mainly of adipose tissue.3 The development of these layers
is a highly coordinated process involving complex gene regulatory
networks acting in a temporally resolved integrated way.
A wound is deﬁned as all manner of tissue damage resulting in the dis-
order of the original tissue structure and homeostasis.4 The mecha-
nisms involved in the repair of wounds involve some of themost com-
plex biological processes.5 The wound healing process in the skin
involves three partially overlapping phases: (1) blood clotting and
inﬂammation, (2) new tissue formation, and (3) tissue remodeling46 Molecular Therapy: Nucleic Acids Vol. 8 September 2017 ª 2017 T
This is an open access article under the CC BY-NC-ND license (http:(the longest phase).6,7 These processes result in the wound tissue be-
ing repaired within a relatively short period. The scar tissue, however,
has reduced tensile strength compared to that of healthy skin tissue,7
demonstrating approximately 70% of the tensile strength of healthy
tissue.8Chronic Wounds
Chronic wounds are the result of multifactorial components within
the wound healing process becoming compromised. They can be
deﬁned as a wound that is not continuously progressing toward heal-
ing9 or not healing in a methodical and timely fashion.8 Pathologi-
cally, one of the clearest indicators of a chronic wound is their fail-
ure to re-epithelialize.10 The aging population are among those most
burdened with chronic wounds, and with low keratinocyte cell turn-
over, this is a factor affecting their ability to re-epithelialize.11 In
general, chronic wounds exhibit reduced mitogenic activity
compared to acute wounds, which has been demonstrated not
only in keratinocytes but also in skin ﬁbroblasts.12 It has been shown
that ﬁbroblast cells isolated from Venus leg ulcers have reduced cell
migration properties in comparison to cells isolated from regular
skin.12
Overall, factors affecting healing ability are categorized as either local
and/or systemic inﬂuences. Local refers to causes that directly affect
the characteristics of the wound site itself and systemic factors related
to the general overall health or disease state of the individual, which
affects healing ability. As such, the following sections detail diabetes
and infection as examples of a systemic and local factor, respectively,
which can inﬂuence a wound to become chronically impaired. Differ-
ences in microRNA (miR) expression will also be explored within the
sections miR and Wound Healing to miR Expression in Chronic
Wounds.he Authors.
//creativecommons.org/licenses/by-nc-nd/4.0/).
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Diabetes is a systemic factor that can be linked to wound healing and
affects approximately 3.2 million people in the UK, which accounts
for 6% of the population.13 This population is at risk of developing
chronic non-healing diabetic foot ulcers. The increase in serum
glucose has a signiﬁcant inﬂuence on wound healing due to destruc-
tive effects showcased by hyperglycemia on the physiology of the
affected cells.14 For example, sorbitol, a by-product of glucose meta-
bolism, can accumulate within tissues, resulting in renal and vascular
complications.15 Hypoxic regions are prevalent in diabetic wounds
and are characterized by an absence of endothelial cells, resulting in
reduced angiogenesis and elongation of the inﬂammatory phase. Dia-
betic mice models have shown decreased restoration of vasculature in
diabetic wounds, with hindered endothelial progenitor cell mobiliza-
tion and homing and reduced levels of VEGF, compared to a non-dia-
betic controls in vivo.16
Non-enzymatic glycosylation associated with hyperglycemia also in-
hibits the function of structural and enzymatic peptides.16 Diabetic
animal models of wound healing show decreased rates of granulation.
Likewise, in humans, the ﬁndings were comparable, showing slow
wound maturation and a lower count of ﬁbroblast cells compared
to non-diabetic wound sites.14
Several cellular functions are affected in diabetic wounds, such as
defective T cell immunity, leukocyte chemotaxis, phagocytosis, bacte-
ricidal capacity, and dysfunctions of ﬁbroblasts and epidermal cells.
Taken together, such defects contribute to inadequate clearance of
infection and delayed healing.17
Obesity is intrinsically linked to diabetes (type 2) and impaired
wound healing. By 2050 in the UK, obesity is projected to affect
60% of adult men, 50% of adult women, and 25% of children.18 Obese
patients have been reported to experience wound complications more
frequently in relation to post-surgery healing, such as higher rates of
infection.19 This has been linked to ischemia and hypo-perfusion in
the subcutaneous adipose tissue. Skin folds also harbor microorgan-
isms that thrive in moist areas and contribute to infection and tissue
breakdown.6
Infection is an example of a local factor that is linked to impaired
wound healing. Virtually all open wounds experience colonization
of microorganisms, which typically has no clinical consequence
because no infection is evident. However, infection within a wound
site can inﬂuence the healing process by prolonging the inﬂammatory
phase. This is due to incomplete clearance of the wound site. There-
fore, there is prolonged elevation of cytokines (e.g., interleukin-1
[IL-1] and tumor necrosis factor alpha [TNF-a]), which are pro-in-
ﬂammatory.20 If the bacterial count within the wound is more than
105 colony-forming units per gram (CFUs/g) of tissue, the wound
will not heal, irrespective of the treatment regime (e.g., skin graft
placement and primary sutures).21 Furthermore, no healing will occur
if the b-hemolytic strain of Streptococcus is present at the wound site,
even at less than 105 CFUs/g.22Bacterial bioﬁlms are a huge hurdle to overcome in the healing
process for chronic wounds. A bioﬁlm is an intricate community of
microorganisms, characterized by massive cell densities that are
accompanied by an extracellular polymer matrix, made mainly of
polysaccharides and proteins.23 This matrix is multifunctional, acting
both as a physical protector from biological and pharmaceutical anti-
microbials. Further to this, it facilitates the adhesion of bacteria cells
to surfaces, particularly foreign bodies.
Current Treatments
Gauze has been historically popular for wound dressings. However,
the use of gauze promotes desiccation of the wound base, which is
not advantageous for efﬁcient healing.24 Furthermore, dry gauze often
adheres to the surface of the wound, which can be painful for the pa-
tient upon removal. Such gauze dressings are susceptible to complete
saturation of wound ﬂuid and so can be ineffective in the protection
against bacterial invasion.24,25 Films are alternatives to gauze dress-
ings and can be utilized as multifunctional adhesive dressings, as in
they can be used as primary dressings directly on the wound or alter-
natively as a secondary dressing to secure other primary dressings to
the wound. Film membranes are thin and semi-permeable, enabling
the exchange of oxygen and water vapor to the wound in addition
to preventing liquid and microorganism contaminants.
Topical antiseptic and antibiotic treatments can be employed to
reduce the bioburden of the wound. Limitations associated with
topical antiseptics and antibiotics include toxicity to human tissue
that can lead to prolonged inﬂammation and microbial resistance,
in addition to the necessity for many reapplications to achieve the
desired effects.26 Acetic acid is an example of a topical treatment typi-
cally administered at concentrations of between 0.25% and 1.0%
(v/v). It is effective against most gram-positive and gram-negative or-
ganisms. Acetic acid is an inexpensive product; however, it can cause
cytotoxicity in vitro and has limited activity against bioﬁlms. The
latter is a particular problem associated with chronic wounds.27,28
The management and treatment of chronic wounds is inﬂuenced by
many multifactorial elements; however, the current modes of treat-
ments and dressing are largely inadequate for chronic wounds. There-
fore, miR replacement or inhibitory therapy is an alternative mode of
treatment because miR has the potential to affect an array of down-
stream gene targets.
miR
miRs are instrumental in the regulation of gene expression through the
promotion ofmRNAdegradation and inhibition ofmRNA translation.
Intronic miRs are encoded within a gene transcript precursor, sharing
the same promoter with the encoded gene transcripts.29 Unidentiﬁed
promoters transcribe intergenic miR, located in the non-coding re-
gions. Finally, polycistronic miRs derived from primary transcripts
contain a diverse range of hairpins, giving rise to different miRs.30
The process of miR biogenesis (Figure 1) is a highly complex process.
In mammalian cells, miRs are transcribed by RNA polymerase II.31Molecular Therapy: Nucleic Acids Vol. 8 September 2017 47
Figure 1. Biogenesis of miR
Biogenesis of miR and the resulting post-transcriptional
gene silencing mechanisms. Pri-miR is transcribed within
the nucleus and then cleaved by the DROSHA complex
to form pre-miR. Exportin 5 transports this pre-miR into
the cytoplasm of the cell. There it is further sliced to form
mature miR. This miR then binds with the RISC to form
a RISC-miR complex, which acts as a translational
repressor and degrades mRNA.
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enzyme (i.e., Drosha) into many miR precursors (pre-miRs).32 Dro-
sha and DGCR8/Pasha establish the microprocessor complex, which
cuts the pri-miR at the ssRNA/dsRNA junction found at the base of
the pri-miR hairpins and results in pre-miR production.31 The result-
ing pre-miRs are 65 nt in length, with characteristic stem-loop
hairpin secondary structures.33 The pre-miR is bound by Exportin
5 in the presence of the co-factor Ran-guanine triphosphatase
(Ran-GTP) and is transported to the cell cytoplasm. Once the pre-
miR has moved to the cytoplasm, a second RNase III enzyme (i.e.,
Dicer) processes the pre-miR with the help of several co-factors
(e.g., double-stranded RNA-activated protein kinase [PACT] and
TAR RNA-binding protein [TRBP]).34 Processing by Dicer leads to
a mature miR strand and an opposing strand that degrades. Thus,
the miR is incorporated into the RNA-induced silencing complex
(RISC).35
miR Function
miR modulates gene expression through association of an Argonaute
protein, which loads the miR into the RISC at the 30 end.35 The incor-
porated miR guides the RISC to its speciﬁc mRNA target through
base-pair complementarity, which results in the disruption of
translation.
Depending on the grade of complementarity between the target
mRNA and the miR, two different mechanisms of RISC-mediated
gene regulation may ensue. In the case of almost complete comple-
mentarity, the RISC cleaves the target mRNA, preventing transla-
tion.33 In the case of imperfect complementarity, translation is sup-
pressed by miR decapping and/or deadenylation (Figure 1).31
miR and Wound Healing
Several studies have demonstrated that miR expression is upregu-
lated or downregulated during the overlapping phases of wound
healing. Table 1 details key miRs that have been found to be instru-
mental during the different phases of wound healing. Therefore, pro-48 Molecular Therapy: Nucleic Acids Vol. 8 September 2017vided the optimal miR can be identiﬁed, new
therapies could be developed.
miR and the Inflammatory Phase
Inﬂammatory response and resolve is para-
mount to successful and rapid wound healing.
Due to the tight regulation of pro-inﬂammatoryand anti-inﬂammatory signaling, disruption of miR biogenesis may
result in an imbalance of these signals adversely affecting the healing
cascade. Evolving studies demonstrate that miR-21, miR-146a/b, and
miR-155 play key roles in regulating the inﬂammatory process.
miR-146 and miR-155 are promoted by TNF-a and IL-1b, and
miR-146 has been shown to silence interleukin-1 receptor-associated
kinase 1 (IRAK) and cyclooxygenase-2 (COX2), whereas miR-155 si-
lences Src homology 2 domain-containing inositol 5-phosphatase
(SHIP1), suppressor of cytokine signaling 1 (SOCS1), and IL-12.36,37
miR and the Proliferation Phase
Proliferation of keratinocyte cells is critical for re-epithelialization of
the wound, ergo miR regulation is vital. For this process to be efﬁcient
and progress rapidly, an abundant oxygen and nutrient supply is
required and angiogenesis is key. Keratinocytes have been shown to
migrate faster upon silencing of SHIP2 and the enhanced activation
of the serine-threonine protein kinase AKT signaling pathway.38
miR-205 has been shown to suppress SHIP2, a negative regulator of
the AKT pathway and enhance coﬁlin expression by a reduction in
the regulation of phosphor-coﬁlin, which increases cell motility.38
Another important miR is miR-21, which has been shown to be an
inhibitor of phosphatase and tensin homolog PTEN. PTEN inhibits
the AKT pathway, thereby activating many cell survival and prolifer-
ative pathways.
miR and the Remodeling Phase
An important aspect of this phase of wound healing is the deposition of
collagen. It has been observed that miR-29a has a direct inﬂuence on
the expression of collagen at a post-transitional level.39 Fetal skin
from mammals can heal without scarring. However, during advanced
gestation, the transition is to a scarring phenotype.40 miR-192, miR-
29b, and miR-29c are highly induced in the later phase of this process.
Transforming growth factor b (TGF-b) (anti-ﬁbrotic) and proteins
such as SMADs that are involved in the pathways for scar-free healing
are targets ofmiR-29b/c.miR-192 also enhances collagen 1-a-2 expres-
sion through the targeting of SMAD-interacting protein 1 (SIP1).34,41
Table 1. miR Involved in the Normal Wound Healing Process
miR Targets Reference
Pro-
inﬂammatory
miR-155 SOCS1, SHIP1, IL-12 34,65
miR-140 PDGF 66
Anti-
inﬂammatory
miR-16 COX2 67
miR-105 TLR2 68
miR-21 PDCD4, PTEN 34,69
miR-125b TNF-a 70,71
miR-223 Mef2c 72
miR-203 TNF-a, IL-24 73
miR-146a,b
TRAF6, IRAK1, STAT1,
TNF-a, COX2
34,71,74
Proliferation
miR-21 TIMP3, TIAM1 43
miR-31 EMP-1 49,50
miR-155 KGF, FGF-7 75
miR-99 IGF1R, mTOR, AKT1 76
miR-198 DIAPH1, PLAU, LAMC2 77
miR-184 AKT 38,78–80
miR-205 SHIP2, Rho-ROCK1 38
miR-203 RAN, RAPH1 81
miR-210 E2F3, ISCU1, ISCU2 82
miR-483-3p MK2, MK167, YAP1 83
Pro-angiogenic
miR-17-5p TIMP1 34
miR-17-92 TSP-1, CTGF 51,84,85
miR-31 FIH-1, Spred1 86,87
miR-126 Spred1, PIK2R2 79,88,89
miR-130a GAX, HOXA5 90
miR-210 EFNA3 91,92
miR-296 HGS 93
miR-378 Fus-1, Sufu 94
miR-424 CUL2 47
Anti-angiogenic
miR-92a Integrin-a5 34,95
miR-17 JAK1 96
miR-15b VEGF 97
miR-16 VEGF 97
miR-20a MKK3,VEGF 97,98
miR-20b HIF-1a, VEGF 97,99
miR-221 c-kit 100,101
miR-222 c-kit 93,94
miR-320 IGF-1 102,103
miR-503 CCNE1,cdc25A 104
Remodeling
miR-29a TAB-1, collagen I and II 39,105
miR-29b SMADs, b-catenin 106
miR-29c SMADs, b-catenin 107
miR192/215 E-cadherin, SIP1 41,108
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It has also been observed that many miRs expressed during the
normal wound healing process are dysregulated during chronic
wound healing.34 A recent study investigating the expression of
miRs in rodents induced with diabetes showed that 18 miRs were up-
regulated and 65 miRs were downregulated compared to control
wound healing groups (i.e., non-diabetic rodents). Therefore,
many different miRs could be used as a therapeutic in the healing
of chronic wounds.42 On the basis of the amalgamation of these ob-
servations, the following sections explore several speciﬁc miRs and
show how they could be exploited for advanced wound healing
applications.
miR-21
Murine studies have demonstrated that miR-21 plays an important
role in keratinocyte migration and re-epithelialization during wound
healing. miR-21 has been found to be upregulated during wound
healing, coincident with TGF-b temporal expression. Consistently,
knockdown of endogenous miR-21 using a speciﬁc antagomir
dramatically delayed re-epithelialization, possibly due to the reduced
keratinocyte migration. Likewise, Yang et al.43 found that through the
utilization of wound scratch healing assays, transfection with miR-21
signiﬁcantly increased keratinocyte cell migration by 62% compared
to scrambled controls. TIMP3 and TIAM1 are regulated by miR-21
in vitro and in vivo. TIMP3 inhibits the activation of the EDK
pathway with downstream activation of ERK1/2, thus promoting
proliferation. Therefore, it can be postulated that miR-21 promotes
keratinocyte migration and boosts re-epithelialization during skin
wound healing.
miR-21 has also been found to be a key regulator of vascular smooth
muscle cell proliferation and apoptosis via BCL2 activation and PTEN
suppression. It also regulates MMP-2 via the PTEN pathway as a
result of myocardial infarction.44 Inhibition of the PTEN pathway
also activates many downstream targets, such as mTOR, which regu-
lates protein synthesis, glucose homeostasis, autophagy, and prolifer-
ation (Figure 2).45 This suggests that introduction of miR-21 within
the diabetic chronic wound site could have potential as a therapeutic
by increasing the extent of cell migration.46
miR-424
In normal wound healing, miR-424 is upregulated in response to hyp-
oxic conditions (Figure 3).47 It works through the stabilization of
transcription factor HIF-a. In normoxic conditions, oxygen targets
HIF for degradation by post-translational hydroxylation at speciﬁc
prolyl residues domains (PHD) within these subunits. This increases
the afﬁnity for the ubiquitin ligases for proteolytic destruction by the
ubiquitin/proteasome pathway. The oxygen-dependent hydroxyl-
ation process, however, is suppressed during hypoxia, leading to sta-
bilization of HIF-1a and subsequent attachment to its constitutive
partner HIF-1b to induce transactivation. Stabilization of HIF has
been classically known to induce the transcription of coding genes
(e.g., vascular endothelial growth factor [VEGF], erythropoietin,
and nitric oxide synthase-2).48Molecular Therapy: Nucleic Acids Vol. 8 September 2017 49
Figure 2. Therapeutic Wound Healing Targets of
miR-21
Schematic diagram of miR-21 targets TIMP3 and PTEN.
By inhibiting PTEN, miR-21 promotes the activation of
many cell survival pathways. The Akt pathway function-
ality increases; thus, the mTOR pathway, for example, is
heightened, which regulates protein synthesis, mito-
chondrial function, and glucose homeostasis. Nf-kB
inhibits apoptosis and Akt inhibits BAD, which is a pro-
apoptotic pathway.
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govern angiogenesis and metabolic pathways. miR-424 cleaves to
the CUL2 30 UTR and inhibits CUL2 expression. A drop in CUL2
levels leads to the destabilization of VCBCR U3-ligase complex,
which leads to the stabilization and nuclear translocation of HIF-1a
in endothelial cells. In vitro wound scratch assays found that miR-
424 signiﬁcantly increased cell migration, with endothelial cells trans-
fected with miR-424, decreasing the wound width by 40% compared
to a 16% decrease in the control group. Furthermore, angiogenesis
tubular formation assays with endothelial cells transfected with
miR-424 also showed increased tube establishment.47 This miR
(mu-miR-322), which is the rodent homolog of miR-424, has been
demonstrated to downregulate in a diabetic rodent model.42 How-
ever, in rodent models with ischemia, it has been shown that this
miR is signiﬁcantly upregulated.47 If there are prolonged periods of
hypoxia, the natural response of cells is the initiation of apoptosis.
Angiogenesis is crucial for rapid wound healing because it provides50 Molecular Therapy: Nucleic Acids Vol. 8 September 2017nutrients and oxygen to the wound site. With
angiogenesis being compromised in patients
with diabetes, it is crucial that it is stimulated
to progress healing. Furthermore, ﬁbroblasts
that are exposed to prolonged periods of hyp-
oxia may not participate in the formation ofextracellular matrix (ECM), which again causes delays in healing.
miR-424 is, therefore, a promoter of angiogenesis, validated by
in vitro and in vivo rodent models.
miR-31
Human wound healing studies have demonstrated that miR-31 upre-
gulation occurs in keratinocytes at the wound edge during prolifera-
tion. It has also been shown that overexpression of miR-31 increases
proliferation, leading to an increased rate in re-epithelialization.
Given that a low rate of re-epithelialization is typical of chronic
wounds, miR-31 may be able to aid in the rapid closure of the
wound.49
Both TGF-b1 and TGF-b2 have been found to be upregulated
in wounds and promote keratinocyte migration. TGF-b1 and
TGF-b2 receptor binding results in the activation of downstream
SMAD proteins, which in turn induce the expression of TGF-bFigure 3. Therapeutic Wound Healing Targets of
miR-424
Schematic diagram of miR-424 targeting CUL2. By
targeting CUL2, the levels on HIF-1 increase within
the cell and its proteosomal degradation is inhibited.
Elevated HIF-1 increases the transcription of VEGF and
Glut1.
Figure 4. EMP-1 as a Therapeutic Wound Healing
Target of miR-31
Schematic diagram of miR-31 targeting EMP-1. EMP-1
inhibits migration and proliferation of cells; thus, its inhi-
bition will result in an increase of these functions.
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identiﬁed as a suppresser of keratinocyte cell proliferation and
migration (Figure 4). miR-31 expression is regulated by TGF-b2
and is a direct target of EMP-1. Silencing of EMP-1 expression
results in a decreased level of miR-31 in keratinocytes; this suggests
that a high level of EMP-1 during inﬂammation may trigger miR-31
expression.49
Another target of miR-31 is factor-inhibiting HIF-1 (FIH-1) (Fig-
ure 5), which is an asparaginyl B-hydroxylase enzyme. It has been
shown that FIH-1 regulates HIF-1 and subsequently VEGF, thus hav-
ing a direct effect on the rate of angiogenesis. Upregulation of miR-31
would therefore increase the levels of VEGF through the silencing of
FIH-1.50
Furthermore, it has been demonstrated that miR-31 is downregu-
lated in wounds within the diabetic rodent model.42 Taken
together, all the evidence indicates that delivery of miR-31 is a
candidate therapy for the inﬂammatory and proliferative phases
of wound healing.Molecular ThermiR-221 and miR-222
Infection is another key consideration in the
wound healing process, and nitric oxide (NO)
is a potent antibacterial agent. miR-221 and
miR-222 have been found to reduce the expres-
sion of endothelial NO, which is essential for
many cellular functions.51 Many studies have
demonstrated that NO levels are lower in dia-betic wounds.52,53 In vivo studies using eNOS knock-out mice have
demonstrated delayed closure of wounds54 and a reduced rate of
angiogenesis.55 Thus, the silencing of miR-221 and miR-222 could
serve as a potential therapeutic to target infection in chronic wound
healing.
Modes of Upregulating/Downregulating miR
For the introduction of miR into cells, many types of cargo could be
utilized, for example, plasmid DNA coding for speciﬁc miRs to upre-
gulate expression or antagomirs for silencing of expression.56,57 For
this, numerous genetic delivery systems are currently utilized in
research, with viral vectors being the most efﬁcient.58 However, there
are apprehensions surrounding viral vectors as genetic carriers due to
mutagenesis, toxicity, and its limited capacity for genetic cargo.59
Examples of non-viral options include polymers of cationic nature, li-
posomes, and peptides, which exhibit the ability to not only package
genetic cargo, but also deliver it to the nucleus of cells.60 Liposomes
are composed of a membrane composed of lipids, in which nucleic
acid can be encapsulated within. Liposomes can take three forms:
anionic, neutral, and, cationic, with cationic being themost frequentlyFigure 5. FIH-1 as a Therapeutic Wound Healing
Target of miR-31
Schematic diagram of miR-31 targeting FIH-1. Thus,
increasing the levels of HIF-1within the cells. This leads to
an increase in the levels of VEGF, thus increasing
angiogenesis.
apy: Nucleic Acids Vol. 8 September 2017 51
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cell membranes.61 There are many commercial options of cationic
liposomes, such as Lipofectamine RNAi-MAX (Invitrogen)62 or
SiPORT (Invitrogen).63 In vitro assays looking at the efﬁciency of li-
posomes at transfecting non-small-cell lung cancer cells with miR-
29b found that there was a 5-fold increase in their expression
compared to non-treated cells, validating their power as an miR de-
livery system.64 For wound healing, the ideal non-viral delivery vector
must be non-immunogenic and non-toxic so as not to compromise
the already delicate wound tissue.
Conclusions
Utilization of miR presents an attractive proposition for the develop-
ment of therapeutic targets that could act on various pathways asso-
ciated with chronically impaired wound healing. With varying levels
of many miRs during the different phases of wound healing, there are
several possible targets that could be employed.
Examples of primemiR candidates for wound healing includemiR-21
and miR-31. miR-21, a target for the proliferation and inﬂammatory
phase, could stop inﬂammation by targeting PDCD4 and promote
proliferation and cell survival by activation of the mTOR pathway.
miR-31 targets FIH-1; this increases the levels of VEGF intracellu-
larly, which is a key promoter of angiogenesis. A signiﬁcant advantage
of using miRs such as these is that they can be detected in blood
serum. With dose and response correlation being a prevalent issue
within gene therapy options, detection of miRs as biomarkers in
serum will provide translational information with regards to the suc-
cessful delivery of the therapeutic.
However, the rate-limiting factor in the implementation of an miR
therapy is a delivery system. This delivery system must be designed
to overcome extracellular and intercellular barriers to ensure the
successful delivery of the therapeutic cargo to the desired targets
without evoking an immune response. Because it is of principal
importance to maintain an optimum healing environment, it
would be prudent to incorporate a gene therapy delivery system
as part of a dressing instrument. Adopting such a system could
confer multi-functionality with the dressing, ensuring a moist
and protected micro-environment in addition to the efﬁcacious de-
livery of the miR gene therapy. It can be rationalized, therefore,
that miR holds the potential to become a momentous third-gener-
ation nucleic acid therapeutic for the treatment and management
of chronic wounds, provided the optimal targeting and delivery
system can be designed.
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